(Q37784316)

23 August 2017

title

Vascular Dermatan Sulfate and Heparin Cofactor II (English)

1 reference

https://api.crossref.org/works/10.1016/S1877-1173(10)93015-9

4 July 2024

1 reference

Douglas M. Tollefsen

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20807652

4 July 2024

language of work or name

1 reference

1 January 2010

1 reference

Progress in Molecular Biology and Translational Science

23 August 2017

published in

1 reference

23 August 2017

volume

93

1 reference

23 August 2017

page(s)

351-372

1 reference

Dermatan sulfate: new functions from an old glycosaminoglycan

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

Heparin cofactor II modulates the response to vascular injury

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

Mechanisms of glycosaminoglycan activation of the serpins in hemostasis

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

Highly Purified Antithrombin III with Heparin Cofactor Activity Prepared by Disc Electrophoresis

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

Identification of two distinct heparin cofactors in human plasma. Separation and partial purification

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

Identification of two distinct heparin cofactors in human plasma. II. Inhibition of thrombin and activated factor X.

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

Detection of a new heparin-dependent inhibitor of thrombin in human plasma

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

Antithrombin assay - the use of human or bovine thrombin and the observation of a "second" heparin cofactor

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

Heparin cofactor II: cDNA sequence, chromosome localization, restriction fragment length polymorphism, and expression in Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

A new member of the plasma protease inhibitor gene family

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

Murine heparin cofactor II: purification, cDNA sequence, expression, and gene structure

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

Heparin cofactor II, antithrombin-beta and their complexes with thrombin in human tissues

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

Cellular internalization and degradation of antithrombin III-thrombin, heparin cofactor II-thrombin, and alpha 1-antitrypsin-trypsin complexes is mediated by the low density lipoprotein receptor-related protein

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

Serpin structure, mechanism, and function

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

Shape-shifting serpins--advantages of a mobile mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

Structure of a serpin-protease complex shows inhibition by deformation

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

Structural evidence for leucine at the reactive site of heparin cofactor II

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

Inhibition of chymotrypsin by heparin cofactor II

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

Molecular mapping of the thrombin-heparin cofactor II complex

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

Reformable intramolecular cross-linking of the N-terminal domain of heparin cofactor II: effects on enzyme inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

Crystal structures of native and thrombin-complexed heparin cofactor II reveal a multistep allosteric mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

The preferred pathway of glycosaminoglycan-accelerated inactivation of thrombin by heparin cofactor II

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

The heparin binding properties of heparin cofactor II suggest an antithrombin-like activation mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

Activation of heparin cofactor II by heparin oligosaccharides

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

Amino acid residues of heparin cofactor II required for stimulation of thrombin inhibition by sulphated polyanions

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

Highly Sulfated Dermatan Sulfates from Ascidians

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

A unique dermatan sulfate-like glycosaminoglycan from ascidian. Its structure and the effect of its unusual sulfation pattern on anticoagulant activity

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

N-Acetylgalactosamine 4,6-O-sulfate residues mediate binding and activation of heparin cofactor II by porcine mucosal dermatan sulfate

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

Transcytosis: crossing cellular barriers

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

Dermatan sulfate is the predominant antithrombotic glycosaminoglycan in vessel walls: implications for a possible physiological function of heparin cofactor II

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

Respective role of antithrombin III and heparin cofactor II in the in vitro anticoagulant effect of heparin and of various sulphated polysaccharides

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

Heparin cofactor II inhibits arterial thrombosis after endothelial injury

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

Strain-dependent embryonic lethality and exaggerated vascular remodeling in heparin cofactor II-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

The dynamics of thrombin formation

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

Protease-activated receptors in the cardiovascular system

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

Vascular dermatan sulfate regulates the antithrombotic activity of heparin cofactor II

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

Antithrombotic activity of dermatan sulfate in heparin cofactor II-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

Accelerated atherogenesis and neointima formation in heparin cofactor II deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

A model of primary atherosclerosis and post-angioplasty restenosis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

Pathology of Acute and Chronic Coronary Stenting in Humans

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

Altered vascular injury responses in mice deficient in protease-activated receptor-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

Hirulog-like peptide reduces restenosis and expression of tissue factor and transforming growth factor-beta in carotid artery of atherosclerotic rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

Inhibition of chronic vessel wall intimal hyperplasia following acute anticoagulant treatment: relative effects of heparin and dermatan sulphate

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

Molecular basis for the susceptibility of fibrin-bound thrombin to inactivation by heparin cofactor ii in the presence of dermatan sulfate but not heparin

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

Is thrombin a key player in the 'coagulation-atherogenesis' maze?

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

Colocalization of thrombin, PAI-1, and vitronectin in the atherosclerotic vessel wall: A potential regulatory mechanism of thrombin activity by PAI-1/vitronectin complexes

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

Deficiency of tissue factor pathway inhibitor promotes atherosclerosis and thrombosis in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

Heparin cofactor II in atherosclerotic lesions from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

Altered dermatan sulfate structure and reduced heparin cofactor II-stimulating activity of biglycan and decorin from human atherosclerotic plaque

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

Mapping by monoclonal antibody detection of glycosaminoglycans in connective tissues

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

Developmental changes in heparan sulfate expression: in situ detection with mAbs

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

An anticoagulant dermatan sulfate proteoglycan circulates in the pregnant woman and her fetus

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

Placental dermatan sulfate: isolation, anticoagulant activity, and association with heparin cofactor II

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

Heparin cofactor II is a novel protective factor against carotid atherosclerosis in elderly individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

Plasma heparin cofactor II activity is an independent predictor of future cardiovascular events in patients after acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

Heparin cofactor II is an independent protective factor against peripheral arterial disease in elderly subjects with cardiovascular risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

Heparin cofactor II levels do not predict the development of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

High plasma heparin cofactor II activity is associated with reduced incidence of in-stent restenosis after percutaneous coronary intervention.

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

High plasma heparin cofactor II activity protects from restenosis after femoropopliteal stenting

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

Evaluation of heparin cofactor II-thrombin complex as a biomarker on blood spots from mucopolysaccharidosis I, IIIA and IIIB mice

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

Heparin cofactor II–thrombin complex: A biomarker of MPS disease

1 reference

https://api.crossref.org/works/10.1016%2FS1877-1173%2810%2993015-9

7 January 2021

Comparative metabolism and distribution of rabbit heparin cofactor II and rabbit antithrombin in rabbits

series ordinal

49

1 reference

https://api.crossref.org/works/10.1016/S1877-1173(10)93015-9

Administration of a potent antagonist of protease-activated receptor-1 (PAR-1) attenuates vascular restenosis following balloon angioplasty in rats

4 July 2024

series ordinal

73

1 reference

https://api.crossref.org/works/10.1016/S1877-1173(10)93015-9

4 July 2024

Identifiers

1 reference

23 August 2017

1 reference